TCOV
AGIO icon

Trust Company of Vermont’s Agios Pharmaceuticals AGIO Stock Holding History

Trust Company of Vermont’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-18
Closed -$1K – 1015
2019
Q1 		$1K Buy
+18
New +$1.05K ﹤0.01% 941

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Trust Company of Vermont's AGIO Position: Q2 2019 in Review

Trust Company of Vermont sold out of Agios Pharmaceuticals (AGIO) in Q2 2019, closing a stake of 18 shares — an estimated $1K sold.

Trust Company of Vermont first reported a position in AGIO in Q1 2019 and held it in 1 quarter. The position peaked at $1K in Q1 2019. 189 funds tracked by Wall St. Rank hold AGIO as of Q2 2019.

  • Trust Company of Vermont reported no remaining Agios Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Trust Company of Vermont sold 18 Agios Pharmaceuticals shares in Q2 2019, an estimated $1K.
  • Trust Company of Vermont first reported a position in Agios Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Trust Company of Vermont's Agios Pharmaceuticals position peaked at $1K in Q1 2019.
  • 189 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2019.

Based on Trust Company of Vermont's 13F filing for Q2 2019, filed 26 Jul 2019.